In-vivo prime editing market seen reaching $4.52B by 2030

The in-vivo prime editing platform market is projected to rise from $1.26 billion in 2025 to $1.63 billion in 2026, with North America holding the largest share last year. The Business Research Company says the market could reach $4.52 billion by 2030 as gene therapy research, clinical use and delivery technology advance.

Why it matters: - The market sits at the center of genome editing and gene therapy, where precise DNA changes could improve treatment options for inherited disorders and other genetic diseases. - Faster growth in the sector signals more investment, more trials and more commercialization activity across biotech and pharma.

What happened: - The Business Research Company published an outlook on the global in-vivo prime editing platform market on Aug. 13, 2026. - The market is forecast to grow from $1.26 billion in 2025 to $1.63 billion in 2026, a 29.4% CAGR. - The same outlook projects the market will reach $4.52 billion by 2030, at a 29.1% CAGR. - North America held the largest market share in 2025. - Asia-Pacific is projected to post the fastest growth over the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The details: - In-vivo prime editing enables targeted DNA changes inside living organisms. - The method uses a modified CRISPR-Cas enzyme, reverse transcriptase and a prime editing guide RNA, or pegRNA. - The platform can create base changes, insertions or deletions without double-strand DNA breaks. - The technology is designed to correct mutations directly in tissues or organs. - The market’s growth drivers include CRISPR breakthroughs, rising research into genetic disorders, biotechnology funding, academic advances and early gene therapy results. - Demand is also rising for genome editing tools that reduce off-target effects and unintended outcomes. - The World Economic Forum reports that more than 2,000 gene therapies are in development worldwide, about double the level from three years ago. - The company says the strongest future drivers include clinical progress in prime editing, broader use of in-vivo gene therapies, supportive regulation, biotech-pharma partnerships and better delivery methods. - Key trends include precision genome editing, rare disease research, improved delivery systems and more preclinical and clinical trials. - The 2026 report package adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated graphics and tables.

Between the lines: - The forecast points to a field moving from research promise toward clinical and commercial relevance. - Delivery remains a major hurdle, which is why better systems and partnership-driven development are prominent themes in the outlook. - North America’s current lead and Asia-Pacific’s projected acceleration suggest the market is shifting from concentration in established biotech hubs to broader global competition.

What's next: - More preclinical and clinical trials are expected as developers test prime editing across additional indications. - Regulatory support and delivery breakthroughs will likely shape how quickly in-vivo prime editing moves into routine therapeutic use. - Biotech and pharmaceutical collaborations may accelerate platform development and pipeline expansion.

The bottom line: - In-vivo prime editing is moving from a niche genome-editing concept toward a high-growth therapeutic platform, with market size and clinical interest both rising fast. - More information is available in the full report and the free sample.